Men are 150% more likely to die from cancer than women. For many men, making a trip to the doctor seems more of an annoyance than a potentially life-saving measure. Watch the full story at KENS 5

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the publication of positive results from a Phase 2b study of vadadustat, a once-daily oral HIF stabilizer, in development for the treatment of anemia related to chronic kidney […]

As they don their white coats for the first time, a new crop of medical students nationwide is taking an oath — but it may not be the one you think. Read the full story at STAT

The Minimally Invasive Surgeons of Texas team is made up of physicians with a diverse set of skills and responsibilities beyond those witnessed by their patients every day. Read the full story at SYS-CON

Earlier this year, when the FDA granted initial approval to Jentadueto XR and a first-line indication to Invokamet, it gave fresh momentum to an entire category of medications: single pills that combine metformin with some other treatment for type 2 diabetes (T2D).  – See more at: http://www.ajmc.com/journals/evidence-based-diabetes-management/2016/september-2016/as-metformin-combinations-proliferate-questions-arise-about-value#sthash.jAAOQ94L.dpuf Read the full story at AJMC.com